Aesthetic practices are capitalizing on GLP-1 demand, with the skincare-adjacent market expected to reach $2 billion within six years.
The GLP-1 aesthetic-care market—encompassing skincare, injectables, and body-contouring services marketed to patients on semaglutide and tirzepatide—is projected to reach $2 billion by 2030. This represents a nascent but rapidly expanding revenue opportunity as practices position themselves to serve patients experiencing weight loss and seeking skin tightening, facial volume restoration, and body contouring.
The phenomenon creates a dual dynamic: practices can capture incremental injectable and device revenue from GLP-1 patients (who often require filler for volume loss and RF/ultrasound for skin laxity), but they also face competition from primary-care providers and direct-to-consumer weight-loss clinics now offering aesthetic add-ons. Regulatory scrutiny around off-label skincare claims and supervision of non-physician providers in this space remains unsettled.
GLP-1 aesthetic care is projected to reach $2 billion by 2030, creating a new revenue stream for practices.
Practices entering this market should clarify their clinical protocols, ensure proper patient screening for contraindications, and document the medical necessity of aesthetic interventions in GLP-1 patients to withstand payer or regulatory scrutiny.
Source: original report ↗
Frequently asked questions
What is the GLP-1 aesthetic care market and how big is it expected to be?
The GLP-1 aesthetic care market includes skincare, injectables, and body-contouring services marketed to patients on semaglutide and tirzepatide. It's projected to reach $2 billion by 2030, representing a rapidly expanding revenue opportunity for aesthetic practices.
Why do GLP-1 patients need aesthetic treatments?
Patients on GLP-1 medications experience significant weight loss, which often leads to facial volume loss and skin laxity. They typically require dermal fillers for volume restoration and radiofrequency or ultrasound treatments for skin tightening and body contouring.
What are the main competitors in the GLP-1 aesthetic space?
Primary-care providers and direct-to-consumer weight-loss clinics are now offering aesthetic add-ons alongside GLP-1 medications, competing directly with traditional aesthetic practices for this patient population.
What regulatory and compliance issues should medspa owners know about GLP-1 aesthetics?
Regulatory scrutiny around off-label skincare claims and supervision of non-physician providers remains unsettled. Practices must document medical necessity of aesthetic interventions, establish clear clinical protocols, and screen patients for contraindications to withstand payer or regulatory review.
How can aesthetic practices position themselves in the GLP-1 market?
Practices should clarify their clinical protocols for GLP-1 patients, implement proper patient screening for contraindications, and maintain thorough documentation of medical necessity for each aesthetic intervention to build credibility and protect against regulatory challenges.
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/mo
Join the owners who run ahead of the industry. Cancel anytime, one click.
